NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.0122.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.75M | 9.56M | 9.61M | 10.75M | 10.46M |
| Total Other Revenue | 34.00K | 9.00K | 2.00K | 0.00 | 0.00 |
| Total Revenue | 9.78M | 9.57M | 9.61M | 10.75M | 10.46M |
| Cost of Revenue | 3.30M | 3.51M | 3.48M | 4.47M | 4.37M |
| Gross Profit | 6.48M | 6.06M | 6.13M | 6.28M | 6.08M |
| SG&A Expenses | 11.41M | 10.73M | 10.43M | 10.56M | 10.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.76M | 14.27M | 13.94M | 15.08M | 14.56M |
| Operating Income | -4.97M | -4.69M | -4.33M | -4.33M | -4.10M |
| Income Before Tax | -7.21M | -7.61M | -7.75M | -7.89M | -6.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.21 | -7.61 | -7.75 | -7.89 | -6.15 |
| Earnings from Discontinued Operations | -13.00K | -2.51M | -2.92M | -3.23M | -3.50M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.22M | -10.12M | -10.66M | -11.12M | -9.64M |
| EBIT | -4.97M | -4.69M | -4.33M | -4.33M | -4.10M |
| EBITDA | -4.93M | -4.65M | -4.28M | -4.28M | -4.05M |
| EPS Basic | -7.22 | -53.60 | -66.11 | -109.05 | -133.86 |
| Normalized Basic EPS | -3.15 | -8.50 | -14.61 | -25.94 | -38.36 |
| EPS Diluted | -7.22 | -53.60 | -66.11 | -109.05 | -133.86 |
| Normalized Diluted EPS | -3.15 | -8.50 | -14.61 | -25.94 | -38.36 |
| Average Basic Shares Outstanding | 13.56M | 5.77M | 2.19M | 1.13M | 480.20K |
| Average Diluted Shares Outstanding | 13.56M | 5.77M | 2.19M | 1.13M | 480.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |